← Back to Search

Alkylating agents

Loncastuximab Tesirine for Lymphoma

Phase 1

Waitlist Available

Led By George Georges

Research Sponsored by Fred Hutchinson Cancer Center

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up time from receiving loncastuximab tesirine to the first observation of disease progression or death from any cause, whichever occurs first, assessed at 2 years post-autologous stem cell transplantation (asct)

Awards & highlights

Study Summary

This trial is testing a new cancer drug combo & its side effects. It's for people with DLBCL that has come back or didn't respond to treatment before.

Eligible Conditions

Lymphoma
Follicular Lymphoma
Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma
Diffuse Large B-Cell Lymphoma
Large B-Cell Lymphoma
B-Cell Lymphoma

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ time from receiving loncastuximab tesirine to death from any cause, assessed at 2 years post-asct

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~time from receiving loncastuximab tesirine to death from any cause, assessed at 2 years post-asct

This trial's timeline: 3 weeks for screening, Varies for treatment, and time from receiving loncastuximab tesirine to death from any cause, assessed at 2 years post-asct for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Incidence of dose-limiting toxicity (Part 1)

Incidence of toxicity requiring dose delay or modification (Part 2)

Secondary outcome measures

Overall survival

Progression-free survival

Trial Design

1Treatment groups

Experimental Treatment

Group I: Treatment (loncastuximab tesirine, BEAM chemotherapy)Experimental Treatment6 Interventions

PART I (CONDITIONING): Patients receive loncastuximab tesirine IV on day -7, carmustine IV over 2 hours on day -7, etoposide IV over 1-2 hours BID days -6, -5, -4, and -3, cytarabine IV over 1 hour BID on days -6, -5, -4, and -3, and melphalan IV over 15-20 minutes on day -2. Patients undergo peripheral blood ASCT per standard practice on day 0. PART II (MAINTENANCE): Beginning 30-90 days after ASCT, patients receive loncastuximab tesirine IV Q3V for up to 9 cycles in the absence of disease progression or unacceptable toxicity.

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

Autologous Hematopoietic Stem Cell Transplantation

2017

Completed Phase 3

~1730

Cytarabine

2016

Completed Phase 3

~3310

Carmustine

1990

Completed Phase 3

~1790

Melphalan

2008

Completed Phase 3

~1500

Etoposide

2010

Completed Phase 3

~2440

Loncastuximab Tesirine

2022

Completed Phase 2

~50

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

Fred Hutchinson Cancer CenterLead Sponsor

556 Previous Clinical Trials

1,343,268 Total Patients Enrolled

100 Trials studying Lymphoma

6,537 Patients Enrolled for Lymphoma

ADC TherapeuticsUNKNOWN

1 Previous Clinical Trials

24 Total Patients Enrolled

1 Trials studying Lymphoma

24 Patients Enrolled for Lymphoma

George GeorgesPrincipal InvestigatorFred Hutch/University of Washington Cancer Consortium

7 Previous Clinical Trials

137 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are there any vacancies for participants in this experiment?

"This clinical trial is no longer recruiting, as per the data on clinicaltrials.gov; it was posted on December 7th 2022 and last edited November 7th 2022. Despite this study's conclusion, there are over two thousand six hundred sixty one other trials in search of participants right now."

Answered by AI